Abstract 189P
Background
Tertiary lymphoid structures (TLSs) are lymphocyte aggregates that correlate with better prognosis in most cancers. TLSs possess anti-tumor potentials but their compositions and functions vary across cancer types and stages, so our understanding of TLS remains largely descriptive. Current studies are limited to fixed pathological samples for immunohistochemistry or spatial transcriptomics, yielding restricted mRNA content in rare cell types. To study the anti-tumor role of TLS, we choose prostate cancer, cause of one of the highest cancer-related deaths in U.S, as our disease model. Castration-resistant prostate cancer (CRPC) is a devastating disease state with high mortality and limited treatment options, including immune checkpoint therapy (ICT). Due to the positive correlation between TLS and ICT response, we want to promote the anti-tumor potentials of TLS in CRPC.
Methods
We aim to develop a region-specific in situ labeling methodology to capture live TLS cells in CRPC mice for characterizations. Since loss of PTEN is a common mutation in prostate cancer, we employed PB-Cre+;Ptenloxp/loxp mice to elucidate TLS composition and function in CRPC. Through photocatalytic labeling in tissue sections, we covalently tagged biotin to live TLS cells, followed by biotin+ TLS isolation for single-cell RNA sequencing (scRNA-seq) analysis.
Results
Our region-specific labeling method is validated in cell lines and tissue sections, including germinal center (GC) enrichment. Our study identified key clusters within CRPC TLS, including CD8+T, follicular helper T (Tfh), GC B, Mki67+ T/B cells and Naaa+ dendritic cells (DCs), among others. TLS also enriched for certain clones in TCR/BCR repertoires.
Conclusions
Through photocatalytic covalent labeling with biotin, we achieved image-guided labeling of live TLS cells for scRNA-seq and identified TLS-enriched cells with potential functions in antigen presentation, cytotoxicity and antibody secretion. We anticipate detecting changes in TLS signatures and functions following PI3K drug treatment, enabling a comprehensive analysis of TLS. Moreover, we plan to refine our methodology to expand the scope of application in other crucial biomedical research areas.
Legal entity responsible for the study
Peking University.
Funding
Peking University; Shenzhen Bay Laboratory.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract